A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to ...

Detailed price information for Dermata Therapeutics Inc WT (DRMAW-Q) from The Globe and Mail including charting and trades.

NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Revance is proud to announce that Blue Lizard® Australian Sunscreen, the #1 best-selling mineral SPF brand in the U.S.*, is celebrating National ...

Revance stockholders must tender by FEBRUARY 4 DEADLINE for transaction to close Crown's tender offer will expire at one minute past 11:59 p.m. Eastern Time, on February 4, 2025.

Revance (RVNC) announced that privately held Crown Laboratories has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance at a price of $3.10 per share in cash ...

(Reuters) -Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics at a roughly 50% lower price compared to an original agreement signed in August, the companies said on ...

Revance Therapeutics ( (RVNC)) has released its Q3 earnings. Here is a breakdown of the information Revance Therapeutics presented to its investors. Revance Therapeutics, Inc., a biotechnology ...

NASHVILLE, TN - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology firm specializing in pharmaceutical preparations, announced on Friday an extension to the commencement date of a tender ...